Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc. (SUPN)
Filing Type: Form 8-K (Current Report)
Date of Report: February 12, 2026
Subject: Announcement of the timing for the release of Fourth Quarter 2025 financial results.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document serves solely as a notification of an upcoming earnings release.
Material Changes
No material changes to financial performance are reported in this filing. The document announces the scheduled date for the upcoming earnings announcement rather than reporting historical performance data.
Guidance, Outlook, and Management Commentary
- Earnings Release Date: The Company expects to report Fourth Quarter 2025 results after market close on Tuesday, February 24, 2026.
- Conference Call: A conference call and webcast are scheduled for Tuesday, February 24, 2026, at 4:30 p.m. E.T. to discuss the results.
- Exhibits: A press release dated February 12, 2026, is included as Exhibit 99.1.
Investor Verification Checklist
- Verify the actual earnings release and conference call materials on February 24, 2026, for specific financial data.
- Review the press release (Exhibit 99.1) for any qualitative updates on business operations not detailed in the 8-K summary.
- Confirm the trading symbol (SUPN) and exchange (Nasdaq) for accurate market data tracking.